Royalty Pharma PLC Class A RPRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RPRX is a good fit for your portfolio.
News
-
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
-
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
-
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
-
Royalty Pharma Reports Third Quarter 2023 Results
-
PTC Therapeutics stock jumps on royalty deal worth up to $1.5 billion
-
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
-
Royalty Pharma Declares Fourth Quarter 2023 Dividend
-
Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
Trading Information
- Previous Close Price
- $28.45
- Day Range
- $28.29–29.08
- 52-Week Range
- $25.93–42.84
- Bid/Ask
- $26.91 / $29.09
- Market Cap
- $12.85 Bil
- Volume/Avg
- 2.2 Mil / 2.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- 127.36
- Price/Sales
- 5.47
- Dividend Yield
- 2.81%
- Dividend Yield (Forward)
- 2.81%
- Total Yield
- 2.81%
Company Profile
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Value
- Total Number of Employees
- 75
- Website
- https://www.royaltypharma.com
Valuation
|
Metric
|
RPRX
|
|---|---|
Price/Earnings (Normalized) | 127.36 |
Price/Book Value | 2.07 |
Price/Sales | 5.47 |
Price/Cash Flow | 4.53 |
Price/Earnings
RPRX
Financial Strength
|
Metric
|
RPRX
|
|---|---|
Quick Ratio | 13.46 |
Current Ratio | 13.51 |
Interest Coverage | 2.41 |
Quick Ratio
RPRX
Profitability
|
Metric
|
RPRX
|
|---|---|
Return on Assets (Normalized) | −7.35% |
Return on Equity (Normalized) | −20.59% |
Return on Invested Capital (Normalized) | −6.95% |
Return on Assets
RPRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jqcc | $451.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nngykf | $91.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wmfxrp | $89.4 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Qtrvq | $40.7 Bil | |
MRNA
| Moderna Inc | Nycxp | $29.8 Bil | |
ARGX
| argenx SE ADR | Xpdf | $27.8 Bil | |
BNTX
| BioNTech SE ADR | Tsxf | $23.5 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nlzjj | $21.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gbyclt | $17.6 Bil | |
INCY
| Incyte Corp | Fkghw | $12.3 Bil |